Ann: Part 1 Remplir US Market Authorisation Successfully Complete, page-6

Very bold of the company:

"Orthocell is well funded for its current global market expansion strategy and beyond US market clearance for Remplir expected in Q1 CY25"

But I like it. And given past human trials and animal studies in Remplir (and indeed Striate) the company has very good reason to be so confident - I thought I perhaps was being a little too overly confident in calling this Q1 CY25 date myself in the past, it seems not.

"The US addressable market in peripheral nerve repair is estimated to be worth more than US$1.1 billion annually, with an estimated 700,000 procedures where Remplir could be used, completed each year".

That's of course only 4.2% of the world population and its mkt potential in Europe greater and Asia even larger again. I wouldn't put too much faith in the forward forecasts, but extrapolate out and the present world market value of USD $10 billion does not seem unreasonable and the Asia Pacific growth I would agree is the real evetnual growth market for OCC with whoever it partners in sales - presuming another (but bigger) BioHorizons deal:


(https://w.sphericalinsights.com)

I think this could indeed warrant a big Kev' / Paul' "I'm excited".